Why Is PROGYNY INC (PGNY) Stock Down Today?

PGNY stock is down 7.86% to $27.84 in a session marked by a sharp opening gap and subdued trading activity. The stock opened at $25.79, a 14.6% drop from the prior close, and has since traded in a narrow range. The decline appears to be driven by a combination of downward revisions in analyst price targets and mixed guidance from the company in its recent earnings call.

What Happened

Progyny reported record second-quarter 2026 results with revenue rising 5.3% year on year to $350.5 million and Non-GAAP EPS of $0.55, which beat estimates. The company also raised its FY2026 Adjusted EPS guidance to a range of $2.04 to $2.10 from $1.98 to $2.09. However, it narrowed its GAAP EPS guidance to $1.26 to $1.32 from $1.23 to $1.34. For Q3, Progyny sees Adjusted EPS of $0.50 to $0.52, below the $0.52 consensus, and GAAP EPS of $0.30 to $0.33, below the $0.34 estimate. The company also provided sales guidance of $335 million to $345 million, below the $350.185 million estimate. These adjustments, while reflecting a strong performance, may have tempered investor optimism.

Canaccord lowered Progyny’s price target to $35 from $36. Meanwhile, recent insider transactions show multiple executives, including COO Melissa B. Cummings, CFO Mark S. Livingston, and EVP Allison Swartz, selling shares in the past month.

What The Data Shows

The stock opened at $25.79, reaching a high of $28.00 and a low of $25.09, with the last price at $27.81. Trading volume is at 0.5 million shares, or 0.4 times the 3-month average. The stock is currently trading within its 52-week range of $16.10 to $33.06. Progyny has a market cap of $2.5 billion, a P/E ratio of 39.5, and revenue growth of 6.6% trailing twelve months.

What To Watch

Investors should monitor Progyny’s Q3 performance and any further guidance adjustments. The company’s ability to meet or exceed its revised targets will likely influence near-term sentiment.